Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer ...

BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio.

Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline.

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is now ...

Various approaches to such protein redesign have drawbacks. Traditional methods include time-consuming trial and error efforts, and many models in the emerging field ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating ...

According to TipRanks.com, Bonello is a 5-star analyst with an average return of 38.6% and a 68.5% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Adaptive ...

The use of artificial intelligence (AI) has been increasing in scientific research and clinical applications. From determining best treatment options for cancer patients, to identifying novel ...

Hundreds of protein-ligand interactions have been identified through a collaboration between the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Pfizer. Georg ...